Search

Your search keyword '"Cilla, G."' showing total 344 results
Start Over Author "Cilla, G."
344 results on '"Cilla, G."'

1. Child hospital admissions associated with influenza virus infection in 6 Spanish cities (2014–2016)

Author

Aristegui, J., Garrote, E., Larrauri, A., Pérez-Yarza, E.G., Cilla, G., Unsain, M., Contreras, J. Ruiz, García-Ochoa, E., Gordillo, J.C., Sampelayo, T. Hernández, Rodríguez, R., González, F., Mellado, M.J., Calvo, C., Méndez, A., Bustamante, J., Salas, D., Lacasta, C., Ramos, J.T., Illán, M., Mendez, M., Barjuan, M., García, J.J., Urraca, S., Caballero, M., Launes, C., Rodrigo, C., Fàbregas, A., Esmel, R., Antón, A., Moreno, D., Valdivielso, A.I., Piñero, P., Carazo, B., Arístegui Fernández, Javier, González Pérez-Yarza, Eduardo, Mellado Peña, María José, Rodrigo Gonzalo de Liria, Carlos, Hernández Sampelayo, Teresa, García García, Juan José, Ruiz Contreras, Jesús, Moreno Pérez, David, Garrote Llanos, Elisa, Ramos Amador, José Tomás, Cilla Eguiluz, Carlos Gustavo, and Méndez Hernández, María

Published
2019
Full Text
View/download PDF

2. Hospitalizaciones infantiles asociadas a infección por virus de la gripe en 6 ciudades de España (2014-2016)

Author

Aristegui, J., Garrote, E., Larrauri, A., Pérez-Yarza, E.G., Cilla, G., Unsain, M., Contreras, J. Ruiz, García-Ochoa, E., Gordillo, J.C., Sampelayo, T. Hernández, Rodríguez, R., González, F., Mellado, M.J., Calvo, C., Méndez, A., Bustamante, J., Salas, D., Lacasta, C., Ramos, J.T., Illán, M., Mendez, M., Barjuan, M., García, J.J., Urraca, S., Caballero, M., Launes, C., Rodrigo, C., Fàbregas, A., Esmel, R., Antón, A., Moreno, D., Valdivielso, A.I., Piñero, P., Carazo, B., Arístegui Fernández, Javier, González Pérez-Yarza, Eduardo, Mellado Peña, María José, Rodrigo Gonzalo de Liria, Carlos, Hernández Sampelayo, Teresa, García García, Juan José, Ruiz Contreras, Jesús, Moreno Pérez, David, Garrote Llanos, Elisa, Ramos Amador, José Tomás, Cilla Eguiluz, Carlos Gustavo, and Méndez Hernández, María

Published
2019
Full Text
View/download PDF

19. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

Author

Hodcroft E.B., Zuber M., Nadeau S., Vaughan T.G., Crawford K.H.D., Althaus C.L., Reichmuth M.L., Bowen J.E., Walls A.C., Corti D., Bloom J.D., Veesler D., Mateo D., Hernando A., Comas I., González-Candelas F., Goig G.A., Chiner-Oms Á., Cancino-Muñoz I., López M.G., Torres-Puente M., Gomez-Navarro I., Jiménez-Serrano S., Ruiz-Roldán L., Bracho M.A., García-González N., Martínez-Priego L., Galán-Vendrell I., Ruiz-Hueso P., De Marco G., Ferrús M.L., Carbó-Ramírez S., D’Auria G., Coscollá M., Ruiz-Rodríguez P., Roig-Sena F.J., Sanmartín I., Garcia-Souto D., Pequeno-Valtierra A., Tubio J.M.C., Rodríguez-Castro J., Rabella N., Navarro F., Miró E., Rodríguez-Iglesias M., Galán-Sanchez F., Rodriguez-Pallares S., de Toro M., Escudero M.B., Azcona-Gutiérrez J.M., Alberdi M.B., Mayor A., García-Basteiro A.L., Moncunill G., Dobaño C., Cisteró P., García-de-Viedma D., Pérez-Lago L., Herranz M., Sicilia J., Catalán-Alonso P., Muñoz P., Muñoz-Cuevas C., Rodríguez-Rodríguez G., Alberola-Enguidanos J., Nogueira J.M., Camarena J.J., Rezusta A., Tristancho-Baró A., Milagro A., Martínez-Cameo N.F., Gracia-Grataloup Y., Martró E., Bordoy A.E., Not A., Antuori-Torres A., Benito R., Algarate S., Bueno J., del Pozo J.L., Boga J.A., Castelló-Abietar C., Rojo-Alba S., Alvarez-Argüelles M.E., Melon S., Aranzamendi-Zaldumbide M., Vergara-Gómez A., Fernández-Pinero J., Martínez M.J., Vila J., Rubio E., Peiró-Mestres A., Navero-Castillejos J., Posada D., Valverde D., Estévez-Gómez N., Fernandez-Silva I., de Chiara L., Gallego-García P., Varela N., Moreno R., Tirado M.D., Gomez-Pinedo U., Gozalo-Margüello M., Eliecer-Cano M., Méndez-Legaza J.M., Rodríguez-Lozano J., Siller M., Pablo-Marcos D., Oliver A., Reina J., López-Causapé C., Canut-Blasco A., Hernáez-Crespo S., Cordón M.L.A., Lecároz-Agara M.-C., Gómez-González C., Aguirre-Quiñonero A., López-Mirones J.I., Fernández-Torres M., Almela-Ferrer M.R., Gonzalo-Jiménez N., Ruiz-García M.M., Galiana A., Sanchez-Almendro J., Cilla G., Montes M., Piñeiro L., Sorarrain A., Marimón J.M., Gomez-Ruiz M.D., López-Hontangas J.L., González Barberá E.M., Navarro-Marí J.M., Pedrosa-Corral I., Sanbonmatsu-Gámez S., Pérez-González C., Chamizo-López F., Bordes-Benítez A., Navarro D., Albert E., Torres I., Gascón I., Torregrosa-Hetland C.J., Pastor-Boix E., Cascales-Ramos P., Fuster-Escrivá B., Gimeno-Cardona C., Ocete M.D., Medina-Gonzalez R., González-Cantó J., Martínez-Macias O., Palop-Borrás B., de Toro I., Mediavilla-Gradolph M.C., Pérez-Ruiz M., González-Recio Ó., Gutiérrez-Rivas M., Simarro-Córdoba E., Lozano-Serra J., Robles-Fonseca L., de Salazar A., Viñuela-González L., Chueca N., García F., Gómez-Camarasa C., Carvajal A., de la Puente R., Martín-Sánchez V., Fregeneda-Grandes J.-M., Molina A.J., Argüello H., Fernández-Villa T., Farga-Martí M.A., Domínguez-Márquez V., Costa-Alcalde J.J., Trastoy R., Barbeito-Castiñeiras G., Coira A., Pérez-del-Molino M.L., Aguilera A., Planas A.M., Soriano A., Fernandez-Cádenas I., Pérez-Tur J., Marcos M.Á., Moreno-Docón A., Viedma E., Mingorance J., Galán-Montemayor J.C., Parra-Grande M., Stadler T., Neher R.A., Swiss National Science Foundation, European Commission, University of Basel, ETH Zurich, National Institute of General Medical Sciences (US), National Institute of Allergy and Infectious Diseases (US), Burroughs Wellcome Fund, Instituto de Salud Carlos III, Consejo Superior de Investigaciones Científicas (España), European Research Council, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Howard Hughes Medical Institute, Hodcroft, Emma B. [0000-0002-0078-2212], Zuber, Moira [0000-0002-4275-8739], Nadeau, Sarah [0000-0003-1008-8918], Vaughan, Timothy G. [0000-0001-6220-2239], Crawford, Katharine H. D. [0000-0002-6223-4019], Althaus, Christian L. [0000-0002-5230-6760], Reichmuth, Martina L. [0000-0001-9345-851X], Bowen, John E. [0000-0003-3590-9727], Walls, Alexandra C. [0000-0002-9636-8330], Corti, Davide [0000-0002-5797-1364], Bloom, Jesse D. [0000-0003-1267-3408], Veesler, David [0000-0002-6019-8675], Mateo, David [0000-0002-1590-4163], Hernando de Castro, Alberto [0000-0003-1180-1068], Comas, Iñaki [0000-0001-5504-9408], González-Candelas, Fernando [0000-0002-0879-5798], Stadler, Tanja [0000-0001-6431-535X], Neher, Richard A. [0000-0003-2525-1407], Hodcroft, Emma B., Zuber, Moira, Nadeau, Sarah, Vaughan, Timothy G., Crawford, Katharine H. D., Althaus, Christian L., Reichmuth, Martina L., Bowen, John E., Walls, Alexandra C., Corti, Davide, Bloom, Jesse D., Veesler, David, Mateo, David, Hernando de Castro, Alberto, Comas, Iñaki, González-Candelas, Fernando, Stadler, Tanja, and Neher, Richard A.

Subjects
Phylogenetics, Sars-Cov-2, Viral infection, 0303 health sciences, 2019-20 coronavirus outbreak, Multidisciplinary, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 610 Medicine & health, 3. Good health, law.invention, 03 medical and health sciences, 0302 clinical medicine, Transmission (mechanics), Geography, 360 Social problems & social services, law, Development economics, 030217 neurology & neurosurgery, 030304 developmental biology
Abstract

Following its emergence in late 2019, the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1,2 has been tracked via phylogenetic analysis of viral genome sequences in unprecedented detail3–5. While the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, within Europe travel resumed in the summer of 2020. Here we report on a novel SARS-CoV-2 variant, 20E (EU1), that emerged in Spain in early summer, and subsequently spread across Europe. We find no evidence of increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate 20E (EU1) was introduced hundreds of times to European countries by summertime travelers, likely undermining local efforts to keep SARS-CoV-2 cases low. Our results demonstrate how a variant can rapidly become dominant even in absence of a substantial transmission advantage in favorable epidemiological settings. Genomic surveillance is critical to understanding how travel can impact SARS-CoV-2 transmission, and thus for informing future containment strategies as travel resumes., This work was supported by the Swiss National Science Foundation (SNSF) through grant numbers 31CA30 196046 (to RAN, EBH, CLA), 31CA30 196267 (to TS), European Union’s Horizon 2020 research and innovation programme - project EpiPose (No 101003688) (MLR, CLA), core funding by the University of Basel and ETH Zürich, the National Institute of General Medical Sciences (R01GM120553 to DV), the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to DV), a Pew Biomedical Scholars Award (DV), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (DV and JDB), a Fast Grants (DV), and NIAID grants R01AI141707 (JDB) and F30AI149928 (KHDC). SeqCOVID-SPAIN is funded by the Instituto de Salud Carlos III project COV20/00140, Spanish National Research Council and ERC StG 638553 to IC and BFU2017-89594R from MICIN to FGC. JDB is an Investigator of the Howard Hughes Medical Institute.

Published
2021
Full Text
View/download PDF

22. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

Author

Treviño, Ana, Soriano, Vicente, Poveda, Eva, Parra, Patricia, Cabezas, Teresa, Caballero, Estrella, Roc, Lourdes, Rodríguez, Carmen, Eiros, Jose M., Lopez, Mariola, De Mendoza, Carmen, Rodríguez, C., del Romero, J., Tuset, C., Marcaida, G., Ocete, M. D., Tuset, T., Caballero, E., Molina, I., Aguilera, A., Rodríguez-Calviño, J. J., Navarro, D., Regueiro, B., Benito, R., Gil, J., Borrás, M., Ortiz de Lejarazu, R., Eiros, J. M., Manzardo, C., Miró, J. M., García, J., Paz, I., Calderón, E., Leal, M., Vallejo, A., Abad, M., Dronda, F., Moreno, S., Escudero, D., Trigo, M., Diz, J., Álvarez, P., Cortizo, S., García-Campello, M., Rodríguez-Iglesias, M., Hernández-Betancor, A., Martín, A. M., Ramos, J. M., Gutiérrez, F., Rodríguez, J. C., Gómez-Hernando, C., Guelar, A., Cilla, G., Pérez-Trallero, E., López-Aldeguer, J., Sola, J., Fernández-Pereira, L., Niubó, J., Hernández, M., López-Lirola, A. M., Gómez-Sirvent, J. L., Force, L., Cifuentes, C., Pérez, S., Morano, L., Raya, C., González-Praetorius, A., Pérez, J. L., Peñaranda, M., Mena, A., Montejo, J. M., Roc, L., Martinez-Sapiña, A., Viciana, I., Cabezas, T., Lozano, A., Fernández, J. M., García Bermejo, I., Gaspar, G., García, R., Górgolas, M., Miralles, P., Aldamiz, T., García, F., Suárez, A., Treviño, A., Parra, P., de Mendoza, C., and Soriano, V.

Published
2014
Full Text
View/download PDF

23. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

Author

Requena, S., Lozano, AB., Caballero, E., García, F., Nieto, MC., Téllez, R., Fernández, JM., Trigo, M., Rodríguez-Avial, I., Martín-Carbonero, L., Miralles, P., Soriano, V., de, Mendoza, C., HIV-2 Spanish Study Group, Rodríguez, C., Vera, M., Del, Romero, J., Marcaida, G., Ocete, MD., Aguilera, A., BENITO, R., de, Lejarazu, RO., Rojo, S., Eirós, JM., Ramos, C., García, J., Paz, I., Diz, J., García-Campello, M., Rodríguez-Iglesias, M., Hernández-Betancor, A., Martín, AM., Ramos, JM., Gimeno, A., Sánchez, V., Gómez-Hernando, C., Cilla, G., Pérez-Trallero, E., Fernández-Pereira, L., Niubó, J., Hernández, M., López-Lirola, AM., Gómez-Sirvent, JL., Force, L., Cabrera, J., Pérez, S., Morano, L., Raya, C., González-Praetorius, A., Cifuentes, C., Peñaranda, M., Montejo, JM., Roc, L., Viciana, I., Fernández-Fuertes, E., García-Bermejo, I., Gaspar, G., Górgolas, M., Pérez, L., Valeiro, M., Aldamiz, T., Margall, N., Suárez, A., Benítez-Gutiérrez, L., Cuervas-Mons, V., and Barreiro, P.

Subjects
virus diseases
Abstract

Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.

Published
2020

24. Viral Infections of The Central Nervous System in Spain: A Prospective Study

Author

de Ory, F., Avellón, A., Echevarría, J. E., Sánchez-Seco, M. P., Trallero, G., Cabrerizo, M., Casas, I., Pozo, F., Fedele, G., Vicente, D., Pena, M. J., Moreno, A., Niubo, J., Rabella, N., Rubio, G., Pérez-Ruiz, M., Rodríguez-Iglesias, M., Gimeno, C., Eiros, J. M., Melón, S., Blasco, M., López-Miragaya, I., Varela, E., Martinez-Sapiña, A., Rodríguez, G., Marcos, M.Á., Gegúndez, M. I., Cilla, G., Gabilondo, I., Navarro, J. M., Torres, J., Aznar, C., Castellanos, A., Guisasola, M. E., Negredo, A. I., Tenorio, A., and Vázquez-Morón, S.

Published
2013
Full Text
View/download PDF

25. Drug resistance mutations in patients infected with HIV-2 living in Spain

Author

Treviño, Ana, de Mendoza, Carmen, Caballero, Estrella, Rodríguez, Carmen, Parra, Patricia, Benito, Rafael, Cabezas, Teresa, Roc, Lourdes, Aguilera, Antonio, Soriano, Vincent, Rodríguez, C., del Romero, J., Tuset, C., Marcaida, G., Tuset, T., Caballero, E., Molina, I., Aguilera, A., Rodríguez-Calviño, J. J., Cortizo, S., Regueiro, B., Benito, R., Borrás, M., Ortiz de Lejarazu, R., Eiros, J. M., Miró, J. M., Lopez-Dieguez, M., Gutiérrez, M. M., Pumarola, T., García, J., Paz, I., Calderón, E., Medrano, F. J., Leal, M., Capote, F., Vallejo, A., Dronda, F., Moreno, S., Escudero, D., Pujol, E., Trigo, M., Diz, J., Álvarez, P., García-Campello, M., Rodríguez-Iglesias, M., Martín, A.M., Hernandez-Betancor, A., Ramos, J. M., Rodríguez, J. C., Gutiérrez, F., Gómez-Hernando, C., Guelar, A., Cilla, G., Pérez-Trallero, E., López-Aldeguer, J., Sola, J., Fernández-Pereira, L., Niubó, J., Veloso, S., Torres, A., López Lirola, A. M., Gómez Sirvent, J. L., Force, L., Cifuentes, C., García, J., Pérez, S., Raya, C., González-Praetorius, A., Mena, A., Pérez, J. L., Peñaranda, M., Montejo, J. M., Gutiérrez, M., Domingo, P., Roc, L., Martinez Sapiña, A., Viciana, I., Cabezas, T., Lozano, A., Fernandez, J. M., García, I., Gaspar, G., García, R., Gorgolas, M., Treviño, A., Parra, P., de Mendoza, C., and Soriano, V.

Published
2011
Full Text
View/download PDF

27. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Author

Rondy, M, Kissling, E, Emborg, Hd, Gherasim, A, Pebody, R, Trebbien, R, Pozo, F, Larrauri, A, Mcmenamin, J, Valenciano, M, Kaic, B, Kurecic Filipovic, S, Visekruna-Vucina, V, Pem Novosel, I, Lovric, Z, Petrović, G, Krause, Tg, Fischer, Tk, Lina, B, Falchi, Antonella, Vilcu, Am, Souty, C, Blanchon, T, van der Werf, S, Enouf, V, Behillil, S, Valette, M, Bernard-Stoecklin, S, Lévy-Bruhl, D, Launay, O, Loulergue, P, Lenzi, N, Lesieur, Z, L'Honneur, As, Galtier, F, Agostini, C, Serrand, C, Merle, C, Foulongne, V, Vanhems, P, Lainé, F, Lagathu, G, Carrat, F, Buda, S, Preuss, U, Prahm, K, Schweiger, B, Wedde, M, Heider, A, Martin, M, Biere, B, Duerrwald, R, Domegan, L, Coughlan, L, O’Donnell, J, Joyce, M, Collins, C, Dunford, L, Martin Moran, Josè Manuel, Tuite, G, Duffy, M, Connell, J, de Gascun, C, Rizzo, C, Bella, A, Alfonsi, V, Castrucci, Mr, Puzelli, S, Pagani, E, Ghisetti, V, Pariani, E, Baldanti, F, Palù, G, D'Agaro, P, Ansaldi, F, Affanni, P, Rossolini, Gm, Camilloni, B, Bagnarelli, P, Sanguinetti, M, Atripaldi, L, Chironna, M, Serra, C, Vitale, F, Germinario, C, Orsi, A, Manini, I, Montomoli, E, Napoli, C, Orsi, Gb, Casado, I, Castilla, J, Fernandino, L, Martínez-Baz, I, Ezpeleta, G, Navascués, A, Pérez-García, A, Aguinaga, A, Ezpeleta, C, Meijer, A, van den Brink, S, van der Hoek, W, Goderski, G, Wijsman, L, Bagheri, M, Dijkstra, F, de Lange, M, Marzec, T, Overduin, P, Teirlinck, A, Wentink, E, Donker, G, Marbus, S, van Gageldonk- Lafeber, R, Schneeberger, P, van Oosterheert JJ, Schweitzer, V, Groeneveld, G, Nunes, B, RIBEIRO MACHADO, CARLOS AUGUSTO, Rodrigues, Ap, DIAZ GOMEZ, MARIA VANESSA, Kislaya, I, Guiomar, R, Pechirra, P, Cristóvão, P, Costa, I, Panarra, A, Côrte-Real, R, Poças, J, João Peres, M, García Comas, L, Marisquerena, Mei, Galán, Jc, Folgueira, D, Gonzalez Carril, F, Sancho Martínez, R, Cilla, G, García Cenoz, M, Quiñones Rubio, C, Martinez Ochoa, E, Blasco, M, Gimenez Duran, J, Vanrell, Jm, Reina, J, Castrillejo, D, Gherasim, Am, Delgado, C, Oliva, J, Casas, I, García, M, Latorre, M, Milagro Beamonte AM, Martinez Sapiñ, A, Oribe Amores, M, Aizpurúa, A, Montes, Marco, Zakikhany, K, Brytting, M, Wiman, Å, Carnahan, A, Warburton, F, Djennad, A, Ellis, J, Andrews, N, Marques, D, Cottrell, S, Reynolds, Alexander, Gunson, R, Galiano, M, Lackenby, A, Robertson, C, O’Doherty, M, Sinnathamby, M, Yonova, I, Moore, C, Sartaj, M, de Lusignan, S, Zambon, M, Moren, A, Penttinen, P., Unión Europea, EpiConcept [Paris], Statens Serum Institut [Copenhagen], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Rondy M., Kissling E., Emborg H.-D., Gherasim A., Pebody R., Trebbien R., Pozo F., Larrauri A., McMenamin J., Valenciano M., Kaic B., Filipovic S.K., Visekruna-Vucina V., Novosel I.P., Lovric Z., Petrovic G., Krause T.G., Fische T.K., Lina B., Falchi A., Vilcu A.-M., Souty C., Blanchon T., van der Werf S., Enouf V., Behillil S., Valette M., Bernard-Stoecklin S., Levy-Bruhl D., Launay O., Loulergue P., Lenzi N., Lesieur Z., L'Honneur A.-S., Galtier F., Agostini C., Serrand C., Merle C., Foulongne V., Vanhems P., Laine F., Lagathu G., Carrat F., Buda S., Preuss U., Prahm K., Schweiger B., Wedde M., Heider A., Martin M., Biere B., Duerrwald R., Domegan L., Coughlan L., O'Donnell J., Joyce M., Collins C., Dunford L., Moran J., Tuite G., Duffy M., Connell J., de Gascun C., Rizzo C., Bella A., Alfonsi V., Castrucci M.R., Puzelli S., Pagani E., Ghisetti V., Pariani E., Baldanti F., Palu G., D'Agaro P., Ansaldi F., Affanni P., Rossolini G.M., Camilloni B., Bagnarelli P., Sanguinetti M., Atripaldi L., Chironna M., Serra C., Vitale F., Germinario C., Orsi A., Manini I., Montomoli E., Napoli C., Orsi G.B., Casado I., Castilla J., Fernandino L., Martinez-Baz I., Ezpeleta G., Navascues A., Perez-Garcia A., Aguinaga A., Ezpeleta C., Meijer A., van den Brink S., van der Hoek W., Goderski G., Wijsman L., Bagheri M., Dijkstra F., de Lange M., Marzec T., Overduin P., Teirlinck A., Wentink E., Donker G., Marbus S., van Gageldonk-Lafeber R., Schneeberger P., van Oosterheert J.J., Schweitzer V., Groeneveld G., Nunes B., Machado A., Rodrigues A.P., Gomez V., Kislaya I., Guiomar R., Pechirra P., Cristovao P., Costa I., Panarra A., Corte-Real R., Pocas J., Peres M.J., Comas L.G., Marisquerena M.E.I., Galan J.C., Folgueira M.D., Carril F.G., Martinez R.S., Cilla G., Cenoz M.G., Rubio C.Q., Ochoa E.M., Blasco M., Duran J.G., Vanrell J.M., Reina J., Castrillejo D., Gherasim A.M., Delgado C., Oliva J., Casas I., Garcia M., Latorre M., Beamonte A.M.M., Sapina A.M., Amores M.O., Aizpurua A., Montes M., Zakikhany K., Brytting M., Wiman A., Carnahan A., Warburton F., Djennad A., Ellis J., Andrews N., Marques D., Cottrell S., Reynolds A., Gunson R., Galiano M., Lackenby A., Robertson C., O'Doherty M., Sinnathamby M., Yonova I., Moore C., Sartaj M., de Lusignan S., Zambon M., Moren A., Penttinen P., Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Marc, Rondy, Esther, Kissling, Hanne-Dorthe, Emborg, Alin, Gherasim, Richard, Pebody, Ramona, Trebbien, Francisco, Pozo, Amparo, Larrauri, Jim, Mcmenamin, Marta, Valenciano, D'Agaro, Pierlanfranco, De Lusignan, S, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)

Subjects
0301 basic medicine, Male, Pediatrics, Epidemiology, viruses, Influenza B viru, influenza, influenza vaccine effectiveness, influenza vaccination, case control study, multicentre study, Europe, Europe, case control study, influenza, influenza vaccination, influenza vaccine effectiveness, multicentre study, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Interim, Pandemic, Influenza A Virus, 030212 general & internal medicine, QA, Influenza vaccine effectiveness, Child, media_common, Vaccine Effectiveness, Vaccination, virus diseases, Middle Aged, 3. Good health, Treatment Outcome, Influenza Vaccines, Child, Preschool, H3N2 Subtype, Female, Seasons, Influenza Vaccine, Rapid Communication, Human, Adult, RM, medicine.medical_specialty, Adolescent, Influenza vaccine, 030106 microbiology, Case control study, Multicentre study, European studies, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, 03 medical and health sciences, Virology, Influenza, Human, medicine, media_common.cataloged_instance, Humans, H1N1 Subtype, Vacina Antigripal, European Union, European union, Preschool, Pandemics, Aged, Influenza A Virus, H3N2 Subtype, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Infant, Newborn, Infant, Influenza a, influenza vaccine effectivene, Newborn, Influenza, respiratory tract diseases, Influenza vaccination, Influenza B virus, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Determinantes da Saúde e da Doença, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years. All study teams are very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams, regional epidemiologists who have contributed to the studies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website www.gisaid.org Sí

Published
2018

29. Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals

Author

Roc, L., de Mendoza, C., Fernandez-Alonso, M., Reina, G., Soriano, V., Rodriguez, C., Vera, M., del Romero, J., Marcaida, G., Ocete, M.D., Caballero, E., Molina, I., Aguilera, A., Rodriguez-Calvino, J.J., Navarro, D., Rivero, C., Vilarino, M.D., Benito, R., Algarate, S., Gil, J., de Lejarazu, R.O., Rojo, S., Eiros, J.M., San Miguel, A., Manzardo, C., Miro, J.M., Garcia, J., Paz, I., Poveda, E., Calderon, E., Escudero, D., Trigo, M., Diz, J., Garcia-Campello, M., Rodriguez-Iglesias, M., Hernandez-Betancor, A., Martin, A.M., Ramos, J.M., Gimeno, A., Gutierrez, F., Rodriguez, J.C., Sanchez, V., Gomez-Hernando, C., Cilla, G., Perez-Trallero, E., Lopez-Aldeguer, J., Fernandez-Pereira, L., Niubo, J., Hernandez, M., Lopez-Lirola, A.M., Gomez-Sirvent, J.L., Force, L., Cifuentes, C., Perez, S., Morano, L., Raya, C., Gonzalez-Praetorius, A., Perez, J.L., Penaranda, M., Hernaez-Crespo, S., Montejo, J.M., Martinez-Sapina, A., Viciana, I., Cabezas, T., Lozano, A., Fernandez, J.M., Garcia-Bermejo, I., Gaspar, G., Garcia, R., Gorgolas, M., Vegas, C., Blas, J., Miralles, P., Valeiro, M., Aldamiz, T., Margall, N., Guardia, C., do Pico, E., Polo, I., Aguinaga, A., Ezpeleta, C., Sauleda, S., Piron, M., Gonzalez, R., Barea, L., Jimenez, A., Blanco, L., Suarez, A., Rodriguez-Avial, I., Perez-Rivilla, A., Parra, P., Fernandez, M., Trevino, A., Requena, S., Benitez-Gutierrez, L., Cuervas-Mons, V., Barreiro, P., Corral, O., and Gomez-Gallego, F.

Abstract

Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor-recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain.

Published
2019

30. Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination

Author

Hasso-Agopsowicz, Mateusz, Ladva, Nanji, Lopman, Benjamin, Sanderson, Colin, Cohen, Adam, Tate, Jacqueline, Riveros, Ximena, Henao-Restrepo, Ana Maria, Clark, Andrew E., Ladva, Chandresh Nanji, Alkorta, M, Atchison, C, Banajeh, S, Becker-Dreps, S, Benhafid, M, Bhandari, N, Bodhidatta, L, Braeckman, T, Bwogi, J, de Cassia Compagnoli Carmona, R, Cilla, G., Contreras-Roldan, I, Coulson, B, Cunliffe, N, Dagan, R, Givon, N, Degiuseppe, J, Dhiman, S, Dian, Z, Díaz, J., Dutta, S, Krishnan, T, Manna, B, Fletcher-Lartey, S, Fu, C, Gendrel, D., Ghenghesh, K., Gonzalez Mago, G, De Grazia, S, Grimwood, K, Groome, M, Haque, A., Heininger, U, Houpt, E, Iturriza-Gómara, M., Hungerford, D, Jarquin, C, McCracken, J, Contreras, I, Cordon-Rosales, C, Kaiser-Labusch, P, Kang, G, Kar, S, Kiulia, N, Kotloff, K, Latipov, R, Linhares, A, Lorrot, M., Mandile, M, Mast, C, Mathew, M., Matinon-Torres, F, Matthijnssens, J, Mladenova, Z., Monini, M, Montes, M, Arana, A, Motamedifar, M, Najafi, A, Nelson, T., Nokes, J, Ntoumi, F, Numazaki, K, O’Reilly, C, Ochoa, T, Page, N, Page, A., Langendorf, C, Podkolzin, A, Quach, C, Racz, M, de Rougemont, Alexis, Ruiz-Palacios, G, Saha, S, Satter, S, Soares, L, Sudarmo, S, Shigemura, K, Shirakawa, T, Athiyyah, A, Tagbo, B, Tarr, P, Klein, E., Denno, D, Turner, A., Uzoma, E, Vatosoa, R, Wandera, E, Wikswo, M, Payne, D, Yhu-Chering, H, Yoshikawa, T, Sugata, K, Yuan, Q, Liying, L, Zaman, K., Zhou, X -N, Zhang, S -X, Xu, Wei-Jiang, Serhan, Fatima, Nakamura, Tomoka, Antoni, Sébastien, Agócs, Mary, Murray, Jillian, Cherian, Thomas, Mwenda, Jason, Weldegebriel, Goitom, Biey, Joseph, Cheikh, Dah, Teleb, Nadia, Rahman, Hossam Abdel, Ahmed, Hinda, Daniels, Danni, Videbaek, Dovile, Wasley, Annemarie, Singh, Simarjit, de Oliveira, Lucia, Rey-Benito, Gloria, Sanwogou, N Jennifer, Liyanage, Jayantha, Wijesinghe, Pushpa Ranjan, Batmunkh, Nyambat, Grabovac, Varja, Fox, Kimberley, Paladin, Fem Julia, Henschke, Nicholas, Queensland University of Technology [Brisbane] (QUT), Microbiology Service, Hospital Donostia, Grupo de Investigación en Energía y Medioambiente [Bucaramanga]] (GIEMA), Universidad Industrial de Santander [Bucaramanga] (UIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Tripoli - University Al Fateh, Visva Bharati University, Enteric Virus Unit, Virus Reference Department, Centre for Infections, Health Protection Agency, Department of Virology, National Reference Laboratory of Enteroviruses, National Center of Infectious and Parasitic Diseases [Sofia, Bulgarie] (NCIPD), Friction Stir Laboratory, Brigham Young University (BYU), UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), Centre National de Référence des virus entériques [CHU de Dijon] (CNR virus entériques), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire de sérologie-virologie (CHU de Dijon), Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Institut de biologie moléculaire des plantes (IBMP), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), School of Social and Community Medicine [Bristol], University of Bristol [Bristol], Vaccine Preventable Disease and Immunization, Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), and University of Stavanger

Subjects
rotavirus gastroenteritis, age distribution, rotavirus, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, vaccine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
Abstract

International audience; We sought datasets with granular age distributions of rotavirus-positive disease presentations among children

Published
2019

31. HTLV-1 infection in solid organ transplant donors and recipients in Spain

Author

de Mendoza, Carmen, Roc, Lourdes, Benito, Rafael, Reina, Gabriel, Manuel Ramos, Jose, Gomez, Cesar, Aguilera, Antonio, Rodriguez-Iglesias, Manuel, Garcia-Costa, Juan, Fernandez-Alonso, Miriam, Soriano, Vicente, Rodriguez, C., Vera, M., del Romero, J., Marcaida, G., Ocete, M. D., Caballero, E., Molina, I., Rodriguez-Calvino, J. J., Navarro, D., Rivero, C., Vilarino, M. D., Algarate, S., Gil, J., Ortiz de Lejarazu, R., Rojo, S., Eiros, J. M., San Miguel, A., Manzardo, C., Miro, J. M., Garcia, J., Paz, I., Poveda, E., Calderon, E., Escudero, D., Trigo, M., Diz, J., Garcia-Campello, M., Hernandez-Betancor, A., Martin, A. M., Gimeno, A., Gutierrez, F., Rodriguez, J. C., Sanchez, V., Gomez-Hernando, C., Cilla, G., Perez-Trallero, E., Lopez-Aldeguer, J., Fernandez-Pereira, L., Niubo, J., Hernandez, M., Lopez-Lirola, A. M., Gomez-Sirvent, J. L., Force, L., Cifuentes, C., Perez, S., Morano, L., Raya, C., Gonzalez-Praetorius, A., Perez, J. L., Penaranda, M., Hernaez-Crespo, S., Montejo, J. M., Martinez-Sapina, A., Viciana, I., Cabezas, T., Lozano, A., Fernandez, J. M., Garcia-Bermejo, I., Gaspar, G., Garcia, R., Gorgolas, M., Vegas, C., Blas, J., Miralles, P., Valeiro, M., Aldamiz, T., Margall, N., Guardia, C., do Pico, E., Polo, I., Aguinaga, A., Ezpeleta, C., Sauleda, S., Piron, M., Gonzalez, R., Barea, L., Jimenez, A., Blanco, L., Suarez, A., Rodriguez-Avial, I., Perez-Rivilla, A., Parra, P., Fernandez, M., Trevino, A., Requena, S., Benitez-Gu-tierrez, L., Cuervas-Mons, V., Barreiro, P., Soriano, V., Corral, O., Gomez-Gallego, F., Spanish HTLV Network, Bioquímica y Biología Molecular, Microbiología, Medicina Preventiva, Salud Pública, Soriano, Vicente [0000-0002-4624-5199], Soriano, Vicente, [Mendoza C] Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. Universidad CEU-San Pablo, Madrid, Spain. [Roc L] Hospital Miguel Servet, Zaragoza, Spain. [Benito R] Hospital Lozano Blesa, Zaragoza, Spain. [Reina G] Clínica Universitaria de Navarra, Pamplona, Spain. [Ramos JM] Hospital General Universitario, Alicante, Spain. [Gómez C] Complejo Hospitalario, Toledo, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, 2420 Virología, medicine.medical_treatment, humanos, Myelopathy, Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies::Retrospective Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], 0302 clinical medicine, Medical microbiology, Tropical spastic paraparesis, Infeccions per retrovirus, 030212 general & internal medicine, Trasplantació d'òrgans, teixits, etc - Espanya, mediana edad, anciano, Leukemia, Leucèmia, Immunosuppression, adulto, Middle Aged, Tissue Donors, Geographic Locations::Europe::Spain [GEOGRAPHICALS], Infectious Diseases, trasplante de órganos, virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Deltaretrovirus::infecciones por HTLV-I [ENFERMEDADES], Cèl·lules T, Screening, Paraparesia espástica tropical, Raonament basat en casos, Ubicaciones Geográficas::Europa (Continente)::España [DENOMINACIONES GEOGRÁFICAS], Female, medicine.symptom, Research Article, Adult, medicine.medical_specialty, Virus Diseases::RNA Virus Infections::Retroviridae Infections::Deltaretrovirus Infections::HTLV-I Infections [DISEASES], 030106 microbiology, técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes::estudios retrospectivos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], T cells, Asymptomatic, Health Surveillance of Health Services::Delivery of Health Care::Patient Care::Therapeutics::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Tissue and Organ Harvesting::Organ Transplantation [HEALTH SURVEILLANCE], lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Leucemia de células T adultas, Internal medicine, medicine, VIH (Virus), Humans, Adult T-cell leukaemia, lcsh:RC109-216, Dialysis, Aged, Retrospective Studies, Transplantation, business.industry, HIV (Viruses), estudios retrospectivos, donantes de tejidos, Organ Transplantation, medicine.disease, HTLV-I Infections, Spain, HTLV-1, vigilancia sanitaria de los servicios de salud::prestación sanitaria::asistencia al paciente::terapéutica::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::extracción de tejidos y órganos::trasplante de órganos [VIGILANCIA SANITARIA], Trasplante, HTLV-1 Infection, infecciones por HTLV-I, business
Abstract

Consortia on behalf of the Spanish HTLV Network: C. Rodríguez, M. Vera, J. del Romero, G. Marcaida, M. D. Ocete, E. Caballero, I. Molina, A. Aguilera, J. J. Rodríguez-Calviño, D. Navarro, C. Rivero, M. D. Vilariño, R. Benito, S. Algarate, J. Gil, R. Ortiz de Lejarazu, S. Rojo, J. M. Eirós, A. San Miguel, C. Manzardo, J. M. Miró, J. García, I. Paz, E. Poveda, E. Calderón, D. Escudero, M. Trigo, J. Diz, M. García-Campello, M. Rodríguez Iglesias, A. Hernández Betancor, A. M. Martín, J. M. Ramos, A. Gimeno, F. Gutiérrez, J. C. Rodríguez, V. Sánchez, C. Gómez Hernando, G. Cilla, E. Pérez Trallero, J. López Aldeguer, L. Fernández Pereira, J. Niubó, M. Hernández, A. M. López Lirola, J. L. Gómez Sirvent, L. Force, C. Cifuentes, S. Pérez, L. Morano, C. Raya, A. González Praetorius, J. L. Pérez, M. Peñaranda, S. Hernáez Crespo, J. M. Montejo, L. Roc, A. Martínez Sapiña, I. Viciana, T. Cabezas, A. Lozano, J. M. Fernández, I. García-Bermejo, G. Gaspar, R. García, M. Górgolas, C. Vegas, J. Blas, P. Miralles, M. Valeiro, T. Aldamiz, N. Margall, C. Guardia, E. do Pico, I. Polo, A. Aguinaga, C. Ezpeleta, S. Sauleda, M. Pirón, R. González, L. Barea, A. Jiménez, L. Blanco, A. Suárez, I. Rodríguez Avial, A. Pérez Rivilla, P. Parra, M. Fernández, M. Fernández Alonso, A. Treviño, S. Requena, L. Benítez Gutiérrez, V. Cuervas Mons, C. de Mendoza, P. Barreiro, V. Soriano, O. Corral & F. Gómez-Gallego, [Background]: HTLV-1 infection is a neglected disease, despite infecting 10–15 million people worldwide and severe illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1 associated illnesses due to immunosuppression, screening is being widely considered in the transplantation setting. Herein, we report the experience with universal HTLV testing of donors and recipients of solid organ transplants in a survey conducted in Spain., [Methods]: All hospitals belonging to the Spanish HTLV network were invited to participate in the study. Briefly, HTLV antibody screening was performed retrospectively in all specimens collected from solid organ donors and recipients attended since the year 2008., [Results]: A total of 5751 individuals were tested for HTLV antibodies at 8 sites. Donors represented 2312 (42.2%), of whom 17 (0.3%) were living kidney donors. The remaining 3439 (59.8%) were recipients. Spaniards represented nearly 80%. Overall, 9 individuals (0.16%) were initially reactive for HTLV antibodies. Six were donors and 3 were recipients. Using confirmatory tests, HTLV-1 could be confirmed in only two donors, one Spaniard and another from Colombia. Both kidneys of the Spaniard were inadvertently transplanted. Subacute myelopathy developed within 1 year in one recipient. The second recipient seroconverted for HTLV-1 but the kidney had to be removed soon due to rejection. Immunosuppression was stopped and 3 years later the patient remains in dialysis but otherwise asymptomatic., [Conclusion]: The rate of HTLV-1 is low but not negligible in donors/recipients of solid organ transplants in Spain. Universal HTLV screening should be recommended in all donor and recipients of solid organ transplantation in Spain. Evidence is overwhelming for very high virus transmission and increased risk along with the rapid development of subacute myelopathy.

Published
2019

32. Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals

Author

Roc, Lourdes, de Mendoza, Carmen, Fernandez-Alonso, Miriam, Reina, Gabriel, Soriano, Vicente, Rodriguez, C., Vera, M., del Romero, J., Marcaida, G., Ocete, M. D., Caballero, E., Molina, I, Aguilera, A., Rodriguez-Calvino, J. J., Navarro, D., Rivero, C., Vilarino, M. D., Benito, R., Algarate, S., Gil, J., Ortiz de Lejarazu, R., Rojo, S., Eiros, J. M., San Miguel, A., Manzardo, C., Miro, J. M., Garcia, J., Paz, I, Poveda, E., Calderon, E., Escudero, D., Trigo, M., Diz, J., Garcia-Campello, M., Rodriguez-Iglesias, M., Hernandez-Betancor, A., Martin, A. M., Ramos, J. M., Gimeno, A., Gutierrez, F., Rodriguez, J. C., Sanchez, V, Gomez-Hernando, C., Cilla, G., Perez-Trallero, E., Lopez-Aldeguer, J., Fernandez-Pereira, L., Niubo, J., Hernandez, M., Lopez-Lirola, A. M., Gomez-Sirvent, J. L., Force, L., Cifuentes, C., Perez, S., Morano, L., Raya, C., Gonzalez-Praetorius, A., Perez, J. L., Penaranda, M., Hernaez-Crespo, S., Montejo, J. M., Martinez-Sapina, A., Viciana, I, Cabezas, T., Lozano, A., Fernandez, J. M., Garcia-Bermejo, I, Gaspar, G., Garcia, R., Gorgolas, M., Vegas, C., Blas, J., Miralles, P., Valeiro, M., Aldamiz, T., Margall, N., Guardia, C., do Pico, E., Polo, I, Aguinaga, A., Ezpeleta, C., Sauleda, S., Piron, M., Gonzalez, R., Barea, L., Jimenez, A., Blanco, L., Suarez, A., Rodriguez-Avial, I, Perez-Rivilla, A., Parra, P., Fernandez, M., Trevino, A., Requena, S., Benitez-Gutierrez, L., Cuervas-Mons, V, Barreiro, P., Corral, O., Gomez-Gallego, F., and Spanish HTLV Network

Subjects
0301 basic medicine, medicine.medical_specialty, 030106 microbiology, Case Report, Infectious and parasitic diseases, RC109-216, 030230 surgery, Gastroenterology, 03 medical and health sciences, Myelopathy, 0302 clinical medicine, Two kidney, myelopathy, Internal medicine, medicine, Pharmacology (medical), antiretroviral drugs, Kidney transplantation, business.industry, screening, medicine.disease, Transplantation, Infectious Diseases, Virus type, HTLV-1, business, transplantation
Abstract

Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor–recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain.

Published
2019

33. Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain

Author

de Mendoza, C, Piron, M, Gonzalez, R, Jimenez, A, Caballero, E, Roc, L, Benito, R, Ramos, JM, Soriano, V, Rodriguez, C, Vera, M, del Romero, J, Marcaida, G, Ocete, MD, Molina, I, Aguilera, A, Rodriguez-Calvino, JJ, Navarro, D, Rivero, C, Vilarino, MD, Algarate, S, Gil, J, de Lejarazu, RO, Rojo, S, Eiros, JM, San Miguel, A, Manzardo, C, Miro, JM, Garcia, J, Paz, I, Poveda, E, Calderon, E, Escudero, D, Trigo, M, Diz, J, Garcia-Campello, M, Rodriguez-Iglesias, M, Hernandez-Betancor, A, Martin, AM, Gimeno, A, Gutierrez, F, Rodriguez, JC, Sanchez, V, Gomez-Hernando, C, Cilla, G, Perez-Trallero, E, Lopez-Aldeguer, J, Fernandez-Pereira, L, Niubo, J, Hernandez, M, Lopez-Lirola, AM, Gomez-Sirvent, JL, Force, L, Cifuentes, C, Perez, S, Morano, L, Raya, C, Gonzalez-Praetorius, A, Perez, JL, Penaranda, M, Hernaez-Crespo, S, Montejo, JM, Martinez-Sapina, A, Viciana, I, Cabezas, T, Lozano, A, Fernandez, JM, Garcia-Bermejo, I, Gaspar, G, Garcia, R, Gorgolas, M, Vegas, C, Blas, J, Miralles, P, Valeiro, M, Aldamiz, T, Margall, N, Guardia, C, do Pico, E, Polo, I, Aguinaga, A, Ezpeleta, C, Sauleda, S, Torres, P, Blanco, L, Suarez, A, Rodriguez-Avial, I, Perez-Rivilla, A, Parra, P, Fernandez, M, Fernandez-Alonso, M, Trevino, A, Requena, S, Benitez-Gutierrez, L, Cuervas-Mons, V, Barreiro, P, Corral, O, and Gomez-Gallego, F

Subjects
myelopathy, adult T-cell leukemia, HTLV-1, screening, epidemiology
Abstract

Background. Although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses. Methods. A nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation. Results. A total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or Strongyloides stercoralis infestation (n = 8; 14%). Human T-cell leukemia virus type 1 diagnosis had been made either at blood banks (n = 109; 44%) or at clinics (n = 138; 56%). It is interesting to note that Spaniards and especially Africans were overrepresented among patients presenting with HTLV-1-associated illnesses, suggesting that misdiagnosis and late presentation are more frequent in these populations compared to Latin Americans. Conclusions. Given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses.

Published
2019

34. HIV co-infection in HTLV-1 carriers in Spain

Author

de Mendoza, C, Caballero, E, Aguilera, A, Benito, R, Macia, D, Garcia-Costa, J, Soriano, V, Rodriguez, C, Vera, M, del Romero, J, Marcaida, G, Ocete, MD, Molina, I, Rodriguez-Calvino, JJ, Navarro, D, Rivero, C, Vilarino, MD, Algarate, S, Gil, J, de Lejarazu, RO, Rojo, S, Eiros, JM, San Miguel, A, Manzardo, C, Mira, JM, Garcia, J, Paz, I, Poveda, E, Calderon, E, Escudero, D, Trigo, M, Diz, J, Garcia-Campello, M, Rodriguez-Iglesias, M, Hernandez-Betancor, A, Martin, AM, Ramos, JM, Gimeno, A, Gutierrez, F, Rodriguez, JC, Sanchez, V, Gomez-Hernando, C, Cilla, G, Perez-Trallero, E, Lopez-Aldeguer, J, Fernandez-Pereira, L, Niubo, J, Hernandez, M, Lopez-Lirola, AM, Gomez-Sirvent, JL, Force, L, Cifuentes, C, Raya, C, Gonzalez-Praetorius, A, Perez, JL, Penaranda, M, Hernaez-Crespo, S, Montejo, JM, Roc, L, Martinez-Sapina, A, Viciana, I, Cabezas, T, Lozano, A, Fernandez, JM, Garcia-Bermejo, I, Gaspar, G, Garcia, R, Gorgolas, M, Vegas, C, Blas, J, Miralles, P, Valeiro, M, Aldamiz, T, Margall, N, Guardia, C, do Pico, E, Polo, I, Aguinaga, A, Ezpeleta, C, Sauleda, S, Piron, M, Gonzalez, R, Barea, L, Jimenez, A, Blanco, L, Suarez, A, Rodriguez-Avial, I, Perez-Rivilla, A, Parra, P, Fernandez, M, Fernandez-Alonso, M, Reina, G, Trevino, A, Requena, S, Benitez-Gutierrez, L, Cuervas-Mons, V, Barreiro, P, Corral, O, Gomez-Gallego, F, Perez, S, Morano, L, and Spanish HTLV Network

Subjects
AIDS, Epidemiology, Tropical spastic paraparesis, Adult T-cell leukemia, virus diseases, HIV, HTLV, Co-infection, Antiretroviral therapy, Late diagnosis
Abstract

Background: Human retroviruses HIV and HTLV share transmission routes. HIV widely spread in Spain during the 80 s through injection drug use and sex, and nowadays HIV rates in Spain account for one of the largest in Europe. In contrast, HTLV-1 is not endemic in Spain, despite hosting huge numbers of migrants from highly endemic regions. Herein, we report the rate and main features of the HIV-HTLV co-infected population in Spain. Methods: A national registry exists in Spain for HTLV since year 1989. Data from standardized case report forms and one centralized lab repository were reviewed, especially for the subset with HTLV-HIV co-infection. Results: Up to December 2018, a total of 369 individuals with HTLV-1 had been diagnosed in Spain. 64% of the population were females, and Latin American individuals accounted for 64.5%. Classical HTLV-associated illnesses were found in 12.7% (myelopathy) and 7.6% (leukemia). HIV coinfection was found in 12 (3.2%). Of those, 3 patients (25%) were female and 39 (75%) were of non Spanish origin. All but two harbored HIV-1 subtype B, being non-B variants found in the two West Africans. Exposure had been sexual in most cases, being 4 homosexual men. Seven HTLV-HIV co-infected patients had developed AIDS and two had developed myelopathy. There was no evidence for increased HTLV-1 clinical pathogenicity due to HIV coinfection. Conclusion: HIV coinfection is infrequent (< 5%) among HTLV-1 carriers in Spain. More than half of co-infected patients come from Latin America. Sexual contact is the most frequent risk behavior, being MSM one third of cases. Late diagnosis explains the high rate (9/12) of clinical manifestations in our HIV-HTLV co-infected population.

Published
2019

35. Child hospital admissions associated with influenza virus infection in 6 Spanish cities (2014-2016) Hospitalizaciones infantiles asociadas a infección por virus de la gripe en 6 ciudades de España (2014-2016)

Author

Arístegui Fernández, J., González Pérez-Yarza, E., Mellado Peña, M.J., Rodrigo Gonzalo de Líria, Carlos, Hernández Sampelayo, T., García García, J.J., Ruiz Contreras, J., Moreno Pérez, D., Garrote Llanos, E., Ramos Amador, J.T., Cilla Eguiluz, C.G., Méndez Hernández, M., Aristegui, J., Garrote, E., Larrauri, A., Pérez-Yarza, E.G., Cilla, G., Unsain, M., Contreras, J.R., García-Ochoa, E., Gordillo, J.C., Sampelayo, T.H., Rodríguez, R., González, F., Mellado, M.J., Calvo, C., Méndez, A., Bustamante, J., Salas, D., Lacasta, C., Ramos, J.T., Illán, M., Mendez, M., Barjuan, M., García, J.J., Urraca, S., Caballero, M., Launes, C., Fábregas Martori, Ana, Esmel Vilomara, Roger, Antón, Andrés, Moreno, D., Valdivielso, A.I., Piñero, P., and Carazo, B.

Subjects
Virus de la gripe, Hospitalizaciones, Influenza virus, Children, Niños, Hospital admissions
Abstract

Introduction: There are only a limited number of studies on the impact of influenza in the Spanish child population. The present work intends to increase this knowledge by studying some key aspects, such as the incidence of hospital admissions, clinic variables, comorbidities, and the vaccination status in the hospitalised children. Methods: A retrospective, observational study was conducted by reviewing the medical records of children under 15 years and hospitalised due to community acquired influenza confirmed microbiologically, during 2 ́flu seasons (2014-2015 and 2015-2016). The study was carried out in 10 hospitals of 6 cities, which represent approximately 12% of the Spanish child population. Results: A total of 907 children were admitted to hospital with main diagnosis of influenza infection (447 < 2 years), estimating an average annual rate of hospitalisation incidence of 0.51 cases / 1,000 children (95% CI; 0.48-0.55). Just under half (45%) of the cases had an underlying disease considered a risk factor for severe influenza, and most (74%) had not been vaccinated. The percentage of children with underlying diseases increased with age, from 26% in children < 6 months to 74% in children >10 years. Admission to the PICU was required in 10% (92) of the cases, mainly due to acute respiratory failure. Conclusion: Influenza continues to be an important cause of hospitalisation in the Spanish child population. Children < 6 months of age and children with underlying diseases make up the majority (> 50%) of the cases. Many of the severe forms of childhood influenza that occur today could be avoided if current vaccination guidelines were met.

Published
2019

36. HTLV testing of solid organ transplant donors

Author

de Mendoza, C, Roc, L, Fernandez-Alonso, M, Soriano, V, Rodriguez, C, Vera, M, del Romero, J, Marcaida, G, Ocete, MD, Caballero, E, Aguilera, A, Rodriguez-Calvino, JJ, Rivero, C, Vilarino, MD, Benito, R, Algarate, S, de Lejarazu, RO, Rojo, S, Eiros, JM, Ramos, C, Manzardo, C, Miro, JM, Garcia-Costa, J, Calderon, E, Escudero, D, Trigo, M, Diz, J, Garcia-Campello, M, Rodriguez-Iglesias, M, Hernandez-Betancor, A, Martin, AM, Ramos, JM, Gimeno, A, Sanchez, V, Guzman, M, Gomez-Hernando, C, Echeverria, MJ, Cilla, G, Fernandez-Pereira, L, Hernandez, M, Lopez-Lirola, AM, Gomez-Sirvent, JL, Force, L, Cifuentes, C, Perez, S, Morano, L, Raya, C, Gonzalez-Praetorius, A, Penaranda, M, Nieto, MC, Montejo, JM, Viciana, I, Cabezas, T, Lozano, A, Perez-Camacho, I, Fernandez, JM, Garcia-Bermejo, I, Gaspar, G, Tellez, R, Gorgolas, M, Perez, L, Monsalvo, S, Valeiro, M, Aldamiz, T, Margall, N, Guardia, C, do Pico, E, Sauleda, S, Piron, M, Gonzalez, R, Richart, A, Barea, L, Jimenez, A, Blanco, L, Suarez, A, Rodriguez-Avial, I, Parra, P, Fernandez, M, Reina, G, Trevino, A, Requena, S, Benitez-Gutierrez, L, Cuervas-Mons, V, Barreiro, P, Corral, O, and Gomez-Gallego, F

Published
2019

37. Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain

Author

Requena S, Caballero E, Lozano A, Rios-Villegas M, Benito R, Rojo S, Cabezas T, Macia M, Nieto M, Soriano V, de Mendoza C, Rodriguez C, Vera M, del Romero J, Ocete M, Aguilera A, Amengual M, Cervantes M, Algarate S, de Lejarazu R, Eiros J, Ramos C, Garcia-Costa J, Calderon E, Trigo M, Diz J, Garcia-Campello M, Rodriguez-Iglesias M, Hernandez-Betancor A, Ramos J, Gimeno A, Sanchez V, Gomez-Hernando C, Echeverria M, Cilla G, Perez-Trallero E, Fernandez-Pereira L, Niubo J, Margall N, Hernandez M, Lopez-Lirola A, Gomez-Sirvent J, Force L, Sauca M, Perez S, Morano L, Raya C, Praetorius A, Cifuentes C, Penaranda M, Montejo J, Roc L, Martinez-Sapina A, Viciana I, Perez-Camacho I, Fernandez-Fuertes E, Fernandez J, Bermejo I, Gaspar G, Gorgolas M, Vegas C, Blas J, Tellez R, Perez L, Valeiro M, Aldamiz T, Garcia F, Suarez A, Rodriguez-Avial I, Barreiro P, Gomez-Gallego F, Corral O, Benitez-Gutierrez L, and Cuervas-Mons V

Subjects
HIV-2, HIV-1, virus diseases, antiretrovirals
Abstract

Background: Whereas HIV-1 has spread globally, HIV-2 is mainly found in West Africa where dual HIV-1/HIV-2 coinfection is nowadays uncommon. Herein, we report the rate, main characteristics, and treatment outcomes of all dually infected patients living in Spain. Methods: We identified retrospectively all persons coinfected with HIV-1 recorded at the Spanish HIV-2 registry. Dual infection had been confirmed using PCR in plasma and/or cells, and/or using discriminatory serological tests. Results: From a total of 373 individuals with HIV-2 recorded at the Spanish registry, 34 (9.1%) were coinfected with HIV-1. Compared with HIV-2 monoinfected persons, dually infected patients were more often male (67.6%), presented with lower median CD4(+) cell counts (204 cells/mu l), and had developed more frequently AIDS events (26.5%). Although 61.7% came from West Africa, 6 (17.6%) were native Spaniards. HIV-1 non-B subtypes were recognized in 75% of coinfected patients, being the most prevalent CRF02_AG. At baseline, 45% of dually infected patients had undetectable plasma HIV-2 RNA. After a median follow-up of 32 (13-48) months on antiretroviral therapy, dually infected patients achieved undetectable viremia in 85% for HIV-1, in 80% for HIV-2; and in 70% for both viruses. Median CD4(+) cell counts reached up to 418 cells/mu l. Conclusion: Roughly 9% of individuals with HIV-2 infection living in Spain are coinfected with HIV-1. Overall, 70% of dually infected patients achieved viral suppression for both viruses under antiretroviral therapy. Given the relatively large population of West Africans living in Spain and the continuous migration flow from HIV-2 endemic areas, HIV-1/HIV-2 coinfection should always be excluded at first diagnosis in all HIV-seroreactive persons. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.

Published
2019

38. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

Author

Garcia F, Martin-Carbonero L, Rodriguez C, Vera M, del Romero J, Marcaida G, Ocete M, Caballero E, Aguilera A, Benito R, de Lejarazu R, Rojo S, Eiros J, Ramos C, Garcia J, Paz I, Trigo M, Diz J, Garcia-Campello M, Rodriguez-Iglesias M, Hernandez-Betancor A, Martin A, Ramos J, Gimeno A, Sanchez V, Gomez-Hernando C, Cilla G, Perez-Trallero E, Fernandez-Pereira L, Niubo J, Hernandez M, Lopez-Lirola A, Gomez-Sirvent J, Force L, Cabrera J, Perez S, Morano L, Raya C, Gonzalez-Praetorius A, Cifuentes C, Penaranda M, Nieto M, Montejo J, Roc L, Viciana I, Lozano A, Fernandez-Fuertes E, Fernandez J, Garcia-Bermejo I, Gaspar G, Tellez R, Gorgolas M, Diaz J, Miralles P, Perez L, Valeiro M, Aldamiz T, Margall N, Suarez A, Rodriguez-Avial I, Requena S, Benitez-Gutierrez L, Cuervas-Mons V, de Mendoza C, Barreiro P, and Soriano V

Abstract

Background: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm(3), respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.

Published
2019

39. Epidemiology of HIV-2 infection in Spain

Author

Soriano, V., Gutiérrez, M., Caballero, E., Cilla, G., Fernández, J. L., Aguilera, A., Tuset, C., Dronda, F., Martín, A. M., Carballo, E., López, I., González-Lahoz, J., de Lejarazu, R. Ortiz, Eirós, J. M., Tor, J., Muga, R., Pujol, E., Calderón, E., Leal, M., Martínez-Zapico, R., Pozo, F., del Romero, J., Rodríguez, C., Ulloa, F., Pérez-Trallero, E., Bravo, R., Mas, A., García-Lerma, G., Pérez-Labad, M. L., Gómez-Cano, M., Villalba, N., Heredia, A., Vallejo, A., and Hewlett, I.

Published
1996
Full Text
View/download PDF

41. Human metapneumovirus as cause of severe community-acquired pneumonia in adults : insights from a ten-year molecular and epidemiological analysis

Author

Vidaur, L., Totorika, I., Montes, M., Vicente, D., Rello, J., Cilla, G., Universitat Autònoma de Barcelona, Vidaur, L., Totorika, I., Montes, M., Vicente, D., Rello, J., Cilla, G., and Universitat Autònoma de Barcelona

Abstract

Background: Information on the clinical, epidemiological and molecular characterization of human metapneumovirus in critically ill adult patients with severe community-acquired pneumonia (CAP) and the role of biomarkers identifying bacterial coinfection is scarce. Methods: This is a retrospective epidemiological study of adult patients with hMPV severe CAP admitted to ICU during a ten-year period with admission PSI score ≥ 3. Results: The 92.8% of the 28 patients with severe CAP due to human metapneumovirus were detected during the first half of the year. Median age was 62 years and 60.7% were male. The genotyping of isolated human metapneumovirus showed group B predominance (60.7%). All patients had acute respiratory failure. Median APACHE II and SOFA score were 13 and 6.55, respectively. The 25% were coinfected with Streptococcus pneumoniae. 60.7% of the patients had shock at admission and 50% underwent mechanical ventilation. Seven patients developed ARDS, three of them younger than 60 years and without comorbidities. Mortality in ICU was 14.3%. Among survivors, ICU and hospital stay were 6.5 and 14 days, respectively. Plasma levels of procalcitonin were higher in patients with bacterial coinfection (18.2 vs 0.54; p < 0.05). The levels of C-reactive protein, however, were similar. Conclusion: Human metapneumovirus was associated with severe CAP requiring ICU admission among elderly patients or patients with comorbidities, but also in healthy young subjects. These patients often underwent mechanical ventilation with elevated health resource consumption. While one out of four patients showed pneumococcal coinfection, plasma procalcitonin helped to implement antimicrobial stewardship.

Published
2019

47. Chlamydia trachomatis genotypes A and B from urogenital specimens of patients in Spain : molecular characterization

Author

Pineiro, L., Isaksson, Jenny, Zapico, M., Cilla, G., Herrmann, Björn, Pineiro, L., Isaksson, Jenny, Zapico, M., Cilla, G., and Herrmann, Björn

Abstract

Objectives: Chlamydia trachomatis ompA genotypes A and B, primarily associated with trachoma, were unexpectedly detected in urogenital samples of patients in Spain, a trachoma-free country. In this study, we aimed to explain this finding using analysis of organotropism-related genes and a multilocus sequence typing (MLST) technique. Methods: C trachomatis genotypes A or B were detected in 8/930 (0.9%) infection episodes between 2006 and 2012. In these strains, organotropism-related genes (polymorphic membrane protein gene H, tryptophan synthase gene A, CTA0934, and cytotoxin) were studied. Further, the strains were analysed by MLST, using a polymerase chain reaction that amplifies five highly variable genomic loci (hctB, CT058, CT144, CT172, and pbpB). Amplicons were sequenced and phylogenetic analysis was conducted. Results: Seven strains were detected in the eight infection episodes (in one patient, an identical strain being found in two episodes). Analysis of organotropism-related genes showed that these strains shared genetic features characteristic of genitotropic genotypes but not of trachoma strains. Three strains of genotype A showed a unique and new MLST-sequence type (ST551, allele profile 8-8-2-27-69). The four strains of genotype B belonged to ST138. Conclusions: C. trachomatis ompA genotypes A and B associated with trachoma, but detected sporadically in urogenital samples in trachoma-free countries, may be the result of recombination between strains adapted to trachoma and strains adapted to sexual transmission.

Published
2018
Full Text
View/download PDF

48. Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies

Author

Rondy, M., Kissling, E., Emborg, H. -D., Gherasim, A., Pebody, R., Trebbien, R., Pozo, F., Larrauri, A., Mcmenamin, J., Valenciano, M., Kaic, B., Filipovic, S. K., Visekruna-Vucina, V., Novosel, I. P., Lovric, Z., Petrovic, G., Krause, T. G., Fische, T. K., Lina, B., Falchi, A., Vilcu, A. -M., Souty, C., Blanchon, T., van der Werf, S., Enouf, V., Behillil, S., Valette, M., Bernard-Stoecklin, S., Levy-Bruhl, D., Launay, O., Loulergue, P., Lenzi, N., Lesieur, Z., L'Honneur, A. -S., Galtier, F., Agostini, C., Serrand, C., Merle, C., Foulongne, V., Vanhems, P., Laine, F., Lagathu, G., Carrat, F., Buda, S., Preuss, U., Prahm, K., Schweiger, B., Wedde, M., Heider, A., Martin, M., Biere, B., Duerrwald, R., Domegan, L., Coughlan, L., O'Donnell, J., Joyce, M., Collins, C., Dunford, L., Moran, J., Tuite, G., Duffy, M., Connell, J., de Gascun, C., Rizzo, C., Bella, A., Alfonsi, V., Castrucci, M. R., Puzelli, S., Pagani, E., Ghisetti, V., Pariani, E., Baldanti, F., Palu, G., D'Agaro, P., Ansaldi, F., Affanni, P., Rossolini, G. M., Camilloni, B., Bagnarelli, P., Sanguinetti, Maurizio, Atripaldi, L., Chironna, M., Serra, C., Vitale, F., Germinario, C., Orsi, A., Manini, I., Montomoli, E., Napoli, C., Orsi, G. B., Casado, I., Castilla, J., Fernandino, L., Martinez-Baz, I., Ezpeleta, G., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Meijer, A., van den Brink, S., van der Hoek, W., Goderski, G., Wijsman, L., Bagheri, M., Dijkstra, F., de Lange, M., Marzec, T., Overduin, P., Teirlinck, A., Wentink, E., Donker, G., Marbus, S., van Gageldonk-Lafeber, R., Schneeberger, P., van Oosterheert, J. J., Schweitzer, V., Groeneveld, G., Nunes, B., Machado, A., Rodrigues, A. P., Gomez, V., Kislaya, I., Guiomar, R., Pechirra, P., Cristovao, P., Costa, I., Panarra, A., Corte-Real, R., Pocas, J., Peres, M. J., Comas, L. G., Marisquerena, M. E. I., Galan, J. C., Folgueira, M. D., Carril, F. G., Martinez, R. S., Cilla, G., Cenoz, M. G., Rubio, C. Q., Ochoa, E. M., Blasco, M., Duran, J. G., Vanrell, J. M., Reina, J., Castrillejo, D., Gherasim, A. M., Delgado, C., Oliva, J., Casas, I., Garcia, M., Latorre, M., Beamonte, A. M. M., Sapina, A. M., Amores, M. O., Aizpurua, A., Montes, M., Zakikhany, K., Brytting, M., Wiman, A., Carnahan, A., Warburton, F., Djennad, A., Ellis, J., Andrews, N., Marques, D., Cottrell, S., Reynolds, A., Gunson, R., Galiano, M., Lackenby, A., Robertson, C., O'Doherty, M., Sinnathamby, M., Yonova, I., Moore, C., Sartaj, M., de Lusignan, S., Zambon, M., Moren, A., Penttinen, P., Sanguinetti M. (ORCID:0000-0002-9780-7059), Rondy, M., Kissling, E., Emborg, H. -D., Gherasim, A., Pebody, R., Trebbien, R., Pozo, F., Larrauri, A., Mcmenamin, J., Valenciano, M., Kaic, B., Filipovic, S. K., Visekruna-Vucina, V., Novosel, I. P., Lovric, Z., Petrovic, G., Krause, T. G., Fische, T. K., Lina, B., Falchi, A., Vilcu, A. -M., Souty, C., Blanchon, T., van der Werf, S., Enouf, V., Behillil, S., Valette, M., Bernard-Stoecklin, S., Levy-Bruhl, D., Launay, O., Loulergue, P., Lenzi, N., Lesieur, Z., L'Honneur, A. -S., Galtier, F., Agostini, C., Serrand, C., Merle, C., Foulongne, V., Vanhems, P., Laine, F., Lagathu, G., Carrat, F., Buda, S., Preuss, U., Prahm, K., Schweiger, B., Wedde, M., Heider, A., Martin, M., Biere, B., Duerrwald, R., Domegan, L., Coughlan, L., O'Donnell, J., Joyce, M., Collins, C., Dunford, L., Moran, J., Tuite, G., Duffy, M., Connell, J., de Gascun, C., Rizzo, C., Bella, A., Alfonsi, V., Castrucci, M. R., Puzelli, S., Pagani, E., Ghisetti, V., Pariani, E., Baldanti, F., Palu, G., D'Agaro, P., Ansaldi, F., Affanni, P., Rossolini, G. M., Camilloni, B., Bagnarelli, P., Sanguinetti, Maurizio, Atripaldi, L., Chironna, M., Serra, C., Vitale, F., Germinario, C., Orsi, A., Manini, I., Montomoli, E., Napoli, C., Orsi, G. B., Casado, I., Castilla, J., Fernandino, L., Martinez-Baz, I., Ezpeleta, G., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Meijer, A., van den Brink, S., van der Hoek, W., Goderski, G., Wijsman, L., Bagheri, M., Dijkstra, F., de Lange, M., Marzec, T., Overduin, P., Teirlinck, A., Wentink, E., Donker, G., Marbus, S., van Gageldonk-Lafeber, R., Schneeberger, P., van Oosterheert, J. J., Schweitzer, V., Groeneveld, G., Nunes, B., Machado, A., Rodrigues, A. P., Gomez, V., Kislaya, I., Guiomar, R., Pechirra, P., Cristovao, P., Costa, I., Panarra, A., Corte-Real, R., Pocas, J., Peres, M. J., Comas, L. G., Marisquerena, M. E. I., Galan, J. C., Folgueira, M. D., Carril, F. G., Martinez, R. S., Cilla, G., Cenoz, M. G., Rubio, C. Q., Ochoa, E. M., Blasco, M., Duran, J. G., Vanrell, J. M., Reina, J., Castrillejo, D., Gherasim, A. M., Delgado, C., Oliva, J., Casas, I., Garcia, M., Latorre, M., Beamonte, A. M. M., Sapina, A. M., Amores, M. O., Aizpurua, A., Montes, M., Zakikhany, K., Brytting, M., Wiman, A., Carnahan, A., Warburton, F., Djennad, A., Ellis, J., Andrews, N., Marques, D., Cottrell, S., Reynolds, A., Gunson, R., Galiano, M., Lackenby, A., Robertson, C., O'Doherty, M., Sinnathamby, M., Yonova, I., Moore, C., Sartaj, M., de Lusignan, S., Zambon, M., Moren, A., Penttinen, P., and Sanguinetti M. (ORCID:0000-0002-9780-7059)

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Published
2018

49. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

Author

Rondy, M., Gherasim, A., Casado, I., Launay, O., Rizzo, C., Pitigoi, D., Mickiene, A., Marbus, S. D., Machado, A., Syrjanen, R. K., Pem-Novose, I., Horvath, J. K., Larrauri, A., Castilla, J., Vanhems, P., Alfonsi, V., Ivanciuc, A. E., Kuliese, M., Van Gageldonk-Lafeber, R., Gomez, V., Ikonen, N., Lovric, Z., Ferenczi, A., Moren, A., Pozo, F., Garcia, M., Latorre, M., Omenaca, M., Oribe Amores, M., Munoz, N., Cilla, G., Fernandino, L., Martinez-Baz, I., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Bella, A., Appelgren, E. C., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Mihai, M. E., Cherciu, C. M., Dinu, S., Tecu, C., Nitescu, M., Bacruban, R., Azamfire, D., Dumitrescu, A., Ianosik, E., Ceausu, E., Popescu, C. P., Florescu, S. A., Tardei, G., Bejan, C., Teodor, A., Juganariu, G., Plesca, C., Duca, E., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Agostini, C., Ray, M., Merle, C., Foulongne, V., Lina, B., Laine, F., De Guibert, S., Lagathu, G., Tattevin, P., Jouneau, S., Esvant, A., Le Gallou, T., Carrat, F., Mawuvi, G., Chau, F., Nohynek, H., Haveri, A., Gefenaite, G., Velyvyte, D., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Bagdonas, A., Nunes, B., Kislaya, I., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Bernard, K., Kurecic-Filipovic, S., Visekruna Vucina, V., Topic, A., Papic, N., Budimir, J., Oroszi, B., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., EpiConcept [Paris], Institute of Health 'Carlos III', CIBER de Epidemiología y Salud Pública (CIBERESP), IDISNA, Pamplona, CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Istituto Superiore di Sanità (ISS), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Lithuanian University of health Sciences, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Health and Welfare [Helsinki], Croatian Institute of Public Health [Zagreb] (CIPH), Office of the Chief Medical Officer, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Laboratoire des pathogènes émergents -- Emerging Pathogens Laboratory (LPE-Fondation Mérieux), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institute of Biology Bucharest of Romanian Academy, Epidemiology Department, Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Istituto Superiore di Sanità Rome, Rome, Italy, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), EpiConcept, Unión Europea, CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), F-CRIN, I-REIVAC, Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Center for Epidemiology Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], 'Carol Davila' University of Medicine and Pharmacy, National Institute for Public Health and the Environment [Bilthoven] ( RIVM ), Instituto Nacional de Saúde Doutor Ricardo Jorge, Croatian Institute of Public Health, Zagreb, Hospices Civils de Lyon ( HCL ), Centre International de Recherche en Infectiologie ( CIRI ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-École normale supérieure - Lyon ( ENS Lyon ), Istituto Superiore de Sanita, HAL-UPMC, Gestionnaire, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, 0301 basic medicine, Pediatrics, Epidemiology, Efetividade da Vacina Antigripal, A(H3N2), Influenza, cases control, elderly, hospitalisation, vaccine effectiveness, Elderly, 0302 clinical medicine, vaccine, Outcome Assessment, Health Care, Influenza A Virus, Hospitalisation, awareness, 030212 general & internal medicine, media_common, Vaccine effectiveness, virus diseases, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Middle Aged, Hospitals, 3. Good health, Hospitalization, Influenza Vaccines, H3N2 Subtype, Female, Seasons, influenza, Rapid Communication, Human, Adult, medicine.medical_specialty, Adolescent, Influenza vaccine, 030106 microbiology, Outcome Assessment (Health Care), 03 medical and health sciences, [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology, Virology, Influenza, Human, medicine, Aged, European Union, Humans, Influenza A Virus, H3N2 Subtype, media_common.cataloged_instance, Vacina Antigripal, European union, Cases control, Cases Control, business.industry, Public health, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Influenza a, Confidence interval, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Emergency medicine, [ SDV.IMM.VAC ] Life Sciences [q-bio]/Immunology/Vaccinology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Prevention control, business
Abstract

Members of the I-Move+hospital working group - Portugal: B. Nunes, I. Kislaya, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal). In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate. Funding: The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). info:eu-repo/semantics/publishedVersion

Published
2017

50. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

Author

Rondy, M., Launay, O., Castilla, J., Costanzo, S., Puig-Barbera, J., Gefenaite, G., Larrauri, A., Rizzo, C., Pitigoi, D., Syrjanen, R. K., Machado, A., Filipovic, S. K., Horvath, J. K., Paradowska-Stankiewicz, I., Marbus, S., Moren, A., Valenciano, M., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Ray, M., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Casado, I., Diaz-Gonzalez, J., Guevara, M., Martinez-Baz, I., Fernandino, L., Navascues, A., Ezpeleta, C., Chamorro, J., Barrado, L., Ortega, M. T., De Gaetano Donati, K., Cauda, R., Donato, C., Taccari, F., Campana, L., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., Alfonsi, V., Bella, A., Puzelli, S., Castrucci, M. R., Orsi, A., Ansaldi, F., Manini, I., Montomoli, E., Chironna, M., Germinario, C., Diez-Domingo, J., Sanudo, B., Carratala Munuera, C., Correcher Medina, P., Gil Guillen, V., Larrea Gonzalez, R., Limon Ramirez, R., Mico Esparza, J. L., Mollar Maseres, J., Otero Reigada, M. C., Tortajada Girbes, M., Schwarz Chavarri, G., Ambrozaitis, A., Jancoriene, L., Zablockiene, B., Zagminas, K., Aukse, M., Damuleviciene, G., Grimalauskaite, R., Kuliese, M., Lesauskaite, V., Velyvyte, D., Niesters, H., Stolk, R. P., Zagmines, K., Rahamat-Langendoen, J., Gherasim, A., Pozo, F., Altzibar, J., Arraras, J. G., Cilla, G., Marco, E., Vidal Garcia, M., Omenaca, M., Ivanciuc, A. E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Nohynek, H., Ikonen, N., Haveri, A., Gomez, V., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Visekruna Vucina, V., Kaic, B., Novosel, I. P., Petrovic, G., Ferenczi, A., Oroszi, B., Korczynska, M. R., Brydak, L. B., Cieslik-Tarkota, R., Rozwadowska, B., Skolimowska, G., Hulboj, D., Jakubik, A., Meijer, A., Van Gageldonk-Lafeber, A. B., Research Council of Lithuania, and European Union

Subjects
0301 basic medicine, Male, Veterinary medicine, Immunology and Microbiology (all), medicine.disease_cause, Polymerase Chain Reaction, Aged, Aged, 80 and over, Case-Control Studies, Clinical Laboratory Techniques, Europe, Female, Hospitalization, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Influenza, Human, Respiratory Tract Infections, Seasons, Sentinel Surveillance, Vaccination, Molecular Medicine, Veterinary (all), Public Health, Environmental and Occupational Health, Infectious Diseases, Seasonal influenza, IMOVE+, 0302 clinical medicine, 80 and over, Influenza A Virus, Influenza A virus, 030212 general & internal medicine, Respiratory tract infections, virus diseases, 3. Good health, H3N2 Subtype, Public Health, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Virus, Hospital, 03 medical and health sciences, Repeated Vaccination, Internal medicine, medicine, H1N1 Subtype, Influenza Vaccine Effectiveness, General Veterinary, General Immunology and Microbiology, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, Influenza, Negative case, influenza vaccination, test negative case control, vaccine effectiveness, business
Abstract

In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). The IMOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD financially supported the InNHOVE network. They had no role in study design, data collection, pooled analysis, and publication. We are grateful to all patients, medical staff, study nurses and epidemiologists from the twelve study sites who actively participated in the study. info:eu-repo/semantics/publishedVersion

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results